Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study

References

• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271–281.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF diabetes atlas. 10th. Belgium: Brussels; 2021. [cited 2022 May 05]. Available from: https://www.diabetesatlas.org
   Google Scholar
• Ministry of Health Labour and Welfare. The National Health and Nutrition Survey in Japan 2016.
   Google Scholar
• Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–1307.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020 Feb;43(2):487–493.
   PubMed Web of Science ®Google Scholar
• Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guideline for diabetes 2016. Diabetol Int. 2018 Feb;9(1):1–45.
   PubMed Web of Science ®Google Scholar
• Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig. 2018 Mar 26;9:657–697.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012 Feb 7;8(8):495–502.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):323–334.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Kaku K, Lee J, Mattheus M, et al. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease- results from EMPA-REG OUTCOME®. Circ J. 2017 Jan 25;81(2):227–234.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME® trial. J Diabetes Investig. 2019 May;10(3):760–770.
   PubMed Web of Science ®Google Scholar
• McKeage K. Linagliptin: an update of its use in patients with type 2 diabetes mellitus. Drugs. 2014 Oct;74(16):1927–1946.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019 Sep 24;322(12):1155–1166.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019 Jan 1;321(1):69–79.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Wang G, Rosenstock J, et al. Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA(R) trial. Diabetol Int. 2021 Jan;12(1):87–100.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Yang W, Watada H, et al. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. Diabetol Int. 2020 Apr;11(2):129–141.
   PubMed Web of Science ®Google Scholar
• Vijayakumar TM, Jayram J, and Meghana Cheekireddy V, et al. Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: a systematic updated review. Curr Ther Res Clin Exp. 2017;84:4–9.
   PubMed Web of Science ®Google Scholar
• Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016 Jun 7;164(11):740–751.
   PubMed Web of Science ®Google Scholar
• Wang J-S, Huang C-N, Hung Y-J, et al. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Res Clin Pract. 2013 2013/10/01/;102(1):16–24.
   PubMed Web of Science ®Google Scholar
• Khaladkar K, Mohan B, Khaladkar K, et al. Efficacy and safety of a fixed dose combination of remogliflozin etabonate and vildagliptin in patients with type-2 diabetes mellitus: a randomized, active-controlled, double-blind, Phase III study. J Assoc Physicians India. 2022 Apr;70(4):11–12.
   PubMedGoogle Scholar
• Glund S, Mattheus M, Runge F, et al. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet. Int J Clin Pharmacol Ther. 2017 Apr;55(4):355–367.
   PubMed Web of Science ®Google Scholar
• Lingvay I, Beetz N, Sennewald R, et al. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgrad Med. 2020 May;132(4):337–345.
   PubMed Web of Science ®Google Scholar
• Kaku K, Haneda M, Tanaka Y, et al. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. Diabetes Obes Metab. 2019 Jan;21(1):136–145.
   PubMed Web of Science ®Google Scholar
• Kawamori R, Haneda M, Suzaki K, et al. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2018 Sep;20(9):2200–2209.
   PubMed Web of Science ®Google Scholar
• Watada H, Yamauchi T, and Yamamoto F, et al. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Expert Opin Drug Saf. 2020;19(9):1193–1202.
   PubMed Web of Science ®Google Scholar
• Kaku K, Chin R, and Naito Y, et al. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study. Expert Opin Drug Saf. 2020 Feb;19(2):211–221.
   PubMed Web of Science ®Google Scholar
• Yamamoto F, Unno Y, and Okamura T, et al. Long-Term safety and effectiveness of linagliptin in Japanese patients with type 2 diabetes mellitus: a 3-year post-marketing surveillance study. Diabetes Ther. 2020 Jan;11(1):107–117.
   PubMed Web of Science ®Google Scholar
• Ito T, Naito Y, and Shimmoto N, et al. Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance. Expert Opin Drug Saf. 2021 Mar;20(3):363–372.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009 Jun;53(6):982–992.
   PubMed Web of Science ®Google Scholar
• Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014 Mar;103(3):373–381.
   PubMed Web of Science ®Google Scholar
• Kinduryte Schorling O, Clark D, Zwiener I, et al. Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus. Adv Ther. 2020 Aug;37(8):3463–3484.
   PubMed Web of Science ®Google Scholar
• Yabe D, Yasui A, Ji L, et al. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. J Diabetes Investig. 2019 Mar;10(2):418–428.
   PubMed Web of Science ®Google Scholar
• Amiel SA, Aschner P, Childs B. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019 May;7(5):385–396.
   PubMed Web of Science ®Google Scholar
• Hendrieckx C, Ivory N, Singh H, et al. Impact of severe hypoglycaemia on psychological outcomes in adults with Type 2 diabetes: a systematic review. Diabet Med. 2019 Sep;36(9):1082–1091.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Inagaki N, Kondo K, et al. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017 Jun;19(6):874–882.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Inagaki N, Kondo K, et al. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2018 Jan;20(1):77–84.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Inagaki N, Kondo K, et al. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study. Diabetes Obes Metab. 2018 Feb;20(2):453–457.
   PubMed Web of Science ®Google Scholar
• Ji Q, Ji L, Mu Y, et al. Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: a subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia. Diabetes Obes Metab. 2021 Aug;23(8):1886–1891.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Yang W, Watada H, et al. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA(®) trial. Diabetol Int. 2020 Apr;11(2):129–141.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018 Feb;41(2):356–363.
   PubMed Web of Science ®Google Scholar
• Irace C, Casciaro F, Scavelli FB, et al. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. Cardiovasc Diabetol. 2018 Apr 9;17(1):52.
   PubMedGoogle Scholar
• Araki E, Haneda M, Kasuga M, et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society. J Diabetes Investig. 2017 Jan;8(1):123–125.
   PubMed Web of Science ®Google Scholar
• Kaku K, Yamamoto K, and Fukushima Y, et al. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study. Expert Opin Drug Saf. 2022 Mar 30;1–14 DOI:10.1080/14740338.2022.2054987. Online ahead of print.
   Google Scholar